Last checked at 
3 Aug 2020 07:00
3 August 2020
RTW VENTURE FUND LIMITED(the "Company")
TOTAL VOTING RIGHTS
In accordance with DTR 5.6.1R, as at 31 July 2020 the Company had 179,023,298 Ordinary Shares in issue, each with equal voting rights, and no shares held in Treasury.
This total voting rights figure can be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information, please contact:
RTW Investments, LP Stephanie Sirota, Chief Business OfficerAlexandra Taracanova, PhD, Director of Investor Relations Julia Enright, Business Development Associate
Ocorian Administration (Guernsey) Limited Kevin Smith
| +1 (646) 343 9280
+44 (0) 1481 742 642
|
J.P. Morgan Cazenove William Simmonds Oliver Kenyon James Bouverat (Sales)
Barclays Tom Swerling Andrew Tusa Ryan McCarthy
| +44 (0)20 7742 4000
+44 (0)20 7623 2323 |
About RTW Venture Fund Limited:
RTW Venture Fund Limited (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.
RTW Venture Fund Limited is managed by RTW Investments, LP, a leading US healthcare investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Visit the RTW website at www.rtwfunds.com for more information.